MOUNTAIN VIEW, Calif., Nov. 06, 2022 (GLOBE NEWSWIRE) — HeartStream, Inc., the chief in revolutionizing precision heartcare, right now introduced new trial outcomes that present evaluating sufferers with suspected CAD by making use of superior synthetic intelligence (AI) to CCTA permits for extra correct non-invasive analysis, reduces pointless testing, and affords larger confidence in figuring out sufferers needing remedy.
The outcomes from the Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) trial had been introduced right now as late-breaking medical information on the American Heart Association’s (AHA) Scientific Sessions in Chicago, IL.
“This is the strongest level of scientific evidence yet to support the approach professional guidelines recommend that physicians use to diagnose stable chest pain patients,” stated Pamela Douglas, M.D., MACC, FASE, FAHA, the Ursula Geller Professor for Research in Cardiovascular Disease, Duke University School of Medicine and examine chair of the PRECISE trial. “Combining multiple steps into a Precision Pathway provides a clear path forward for clinicians.”
PRECISE is the primary international randomized managed trial of its type, enrolling 2,103 contributors at 65 websites. The trial confirms that the CCTA ± FFRCT-centered technique, acknowledged by the AHA/ACC Guidelines, is the superior diagnostic pathway for sufferers with suspected coronary artery illness.
The trial compares a non-invasive Precision Pathway to Traditional Testing which incorporates stress testing or invasive cardiac catheterization. The Precision Pathway is in step with the AHA/ACC guideline-recognized strategy that defers testing for low-risk sufferers and exams all others with CCTA ± FFRCT. The FFRCT Analysis makes use of AI coupled with extremely educated analysts to create an interactive 3D laptop mannequin of the guts that quantifies and shows blood stream and blockages.
Compared to Traditional Testing, the PRECISE trial confirmed that the Precision Pathway:
- permits for extra correct non-invasive analysis, considerably reducing the charges of false negatives and false positives in comparison with Traditional Testing in sufferers with coronary artery illness.
- reduces pointless exams, offering a greater affected person expertise, with a 4x discount in pointless invasive catheterization and necessitating fewer preliminary diagnostic exams general.
- gives confidence in treating the suitable sufferers – 75% extra more likely to establish sufferers in want of intervention.
“We’re pleased to see these data support what the guidelines already recognize,” stated Campbell Rogers, MD, FACC, Chief Medical Officer, HeartStream. “We believe this level-one clinical science information will be used by more practitioners to guide decisions on how to optimize care for people with suspected coronary artery disease.”
A CCTA ± FFRCT pathway has been adopted by greater than 725 hospitals worldwide, together with 80% of the Top 50 Heart Hospitals within the US.
About HeartStream
HeartStream is the worldwide chief in revolutionizing precision coronary heart care, uniquely combining human ingenuity with superior AI expertise. Headquartered in Mountain View, California, our expertise has been revealed in additional than 500 peer-reviewed publications that showcase the worth of anatomy, physiology, and plaque. We started our journey to enhance coronary artery illness (CAD) analysis with FFRCT and have now expanded our product portfolio to incorporate anatomic stenosis and plaque info. To date, clinicians have used our expertise for greater than 135,000 sufferers to assist within the analysis of coronary heart illness.1 For extra info, go to www.heartflow.com and join on Twitter and LinkedIn.
Contacts For Media
Linly Ku
HeartStream
[email protected]
1 Data on file at HeartStream
A video accompanying this announcement is out there at https://www.globenewswire.com/NewsRoom/AttachmentNg/aa5a7a5e-9488-4a45-a960-e5c939fb7a73
